The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Brought to you by Scientific Education Support

The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Create an account and access these new features:

Bookmark content to read later

Select your specific areas of interest

View pso content recommended for you

Visual abstract | Real-world efficacy and safety of tildrakizumab in patients with psoriasis

By Haimanti Mandal

Dec 7, 2023

Learning objective: After reading this article, learners will be able to discuss the efficacy and safety of tildrakizumab treatment in patients with moderate-to-severe plaque psoriasis.

Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.

Question 1 of 1

In a real-world study involving Spanish patients with moderate-to-severe plaque psoriasis, what was the approximate reduction in PASI score observed after 24 weeks of treatment with tildrakizumab?

The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract summarizing efficacy and safety of tildrakizumab in a real-world cohort of patients with moderate-to-severe plaque psoriasis in Spain.